Posted on July 22nd, 2016 | By Bill W. Hornaday
Exclamation points are generally a no-no when writing headlines. But here at the Innovate Indiana Blog, we’re going to make an exception — just this once — to make an important and exciting announcement.
Effective Aug. 1, the Innovate Indiana Blog will have a newer, cleaner appearance and a different name to be revealed that same day. As our web development team makes the transition from the old format to the new, the Innovate Indiana Blog will “go dark” for one week starting July 25.
Upon its return, our renovated blog will continue to bring readers news of innovation, technology transfer and commercialization and economic enhancement within the Innovate Indiana universe as we strive to help the Hoosier State generate long-term prosperity through developing a culture of building and making.
Along with regular posts from myself and Steve Martin, the blog will continue to feature guest posts and articles from Innovate Indiana’s executive team, as well as key figures in ingenuity, entrepreneurship and economic development at IU campuses throughout the state.
We hope you enjoy our new format as the Innovate Indiana Blog begins a new chapter in its six-year history.
Posted on July 21st, 2016 | By Steve Martin
Arrhythmotech LLC, which was launched through the Spin Up program at Indiana University Research and Technology Corp., has received a two-year STTR Phase II grant worth $1,472,476 from the National Institutes of Health.
Dr. Peng-Sheng Chen, company co-founder, said the grant will be used on new methods to study patients who are affected by atrial fibrillation.
“The grant will allow us to collaborate with investigators at the Mayo Clinic in Rochester, Minnesota, and at Cedars-Sinai Medical Center in Los Angeles,” he said.
More information about the NIH grant and how Arrhythmotech will benefit is here.
Posted on July 20th, 2016 | By Steve Martin
ApeX Therapeutics, which has received an investment from the Innovate Indiana Fund and licenses technology through Indiana University Research and Technology Corp., has had its Investigational New Drug (IND) application accepted by the U.S. Food and Drug Administration. The company will conduct clinical testing of its lead drug candidate, APX3330, in pancreatic cancer.
Mark R. Kelley, Ph.D., is Scientific Founder of ApeX Therapeutics. He also is the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor of Biochemistry and Molecular Biology and Pharmacology and Toxicology at Indiana University School of Medicine.
Mark R. Kelley
“We are very excited to have reached this very important milestone to evaluate APX3330 in patients with pancreatic cancer,” he said. “We are now poised to initiate the study in the coming months.”
More information about the U.S. FDA acceptance of the IND application is here.
Posted on July 19th, 2016 | By Steve Martin
Axol Bioscience Ltd., based in Cambridgeshire, U.K., has licensed technology developed at the Indiana University School of Medicine.
The license agreement with Indiana University Research and Technology Corp. is for technology that creates cells found on the interior of blood vessels. It was developed by Dr. Mervin C. Yoder and Nutan Prasain, Ph.D.
Mervin C. Yoder
“We developed the methods that were required to direct the differentiation of the stem cells into endothelial colony forming cells, or ECFC, the progenitor cells that give rise to endothelial cells,” Yoder said. “The ECFC-derived endothelial cells display potent proliferative potential and in vivo vessel formation.”
Axol Bioscience will produce the cells and sell them to industrial and academic researchers.
More information about the licensing agreement and the technology are available here.
Posted on July 18th, 2016 | By Bill W. Hornaday
Indiana University’s Council for Regional Engagement and Economic Development (CREED) — a university-wide group that addresses regional economic issues throughout the Hoosier state — will welcome three new members when its next meeting takes place Aug. 24 at IUPUI.
Representing IU East will be Robert Mulligan, incoming dean of the university’s School of Business and Economics, who succeeds outgoing dean David Frantz.
At IU South Bend, P.N. Saksena, interim dean of the Judd Leighton School of Business and Economics, replaces Rob Ducoffe, who was named provost and vice chancellor of academic affairs at the University of Wisconsin-Parkside.
The new representative for IUPU-Columbus will be Greg Knudson, director of the university’s Center for Business and Economic Development. He succeeds Matt Souza, special assistant to IUPUC’s vice chancellor and dean.
“We look forward to the contributions of CREED’s incoming members as we continue to expand collaboration between IU and Indiana’s business community, along with promoting a statewide spirit of entrepreneurship and innovation.”
– Bill Stephan, IU Vice President for Engagement and CREED chair
The dialogue among CREED members identifies ways that IU may bring its resources and expertise to bear to advance the state’s economy. One of CREED’s main resources is its Regional Economic Development, or RED Fund. It provides cost-share grants of up to $2,500 for qualifying proposals submitted through regional campuses.
Read more about CREED’s mission and its newest members here.